drugset / Trial / NCT05351086
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of PUR3100 in Health Adults
RandomizedFactorialQuadruple-blindTreatment
Summary
A Double Dummy, Double-blind Study to Assess the Safety, Tolerability, and Pharmacokinetics of PUR3100 in Healthy Adults
Timeline
- Start
- 2022-06-09
- Primary completion
- 2022-09-22
- Completion
- 2022-09-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dihydroergotamine | Small molecule | 1 mg | Intravenous |
| Subject | PUR3100 | Unknown | 0.5 mg | Inhaled |
| Subject | PUR3100 | Unknown | 1 mg | Inhaled |
| Subject | PUR3100 | Unknown | 1.5 mg | Inhaled |
Indications
No indication recorded.